A University of Wyoming spin-out business has received a 150-thousand dollar grant to improve the effectiveness of drugs that can potentially help diabetes and cancer patients. Christoph Geisler is the chief research scientist for the company GlycoBac. He says the grant is through the National Institutes of Health Small Business Innovation Research Program. It will allow the company to improve the effectiveness of already-produced drugs.
The company was founded by Geisler and UW Molecular Biology Professor Don Jarvis. They hold a licensing agreement that allows them to use genetically engineered insect cells for manufacturing vaccines, diagnostics or therapeutics.